Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

WCC Introduces New Service for Oncology Imaging Studies Involving irRC

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
New service enables combination tumor assessments using both RECIST and irRC.

WorldCare Clinical, LLC (WCC) has announced a new service that enables efficient capture and analysis of both standard tumor assessment, such as RECIST (Response Evaluation Criteria in Solid Tumors), and the newer immune-related response criteria (irRC) simultaneously.

Developed in collaboration with leading academic researchers, WCC’s method has been validated and is being used to evaluate new immune-related treatments.

WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The new service was designed for sponsors developing immunotherapeutic agents who want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.

“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WorldCare Clinical.

Walovitch continued, “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”

WCC Director of Software Engineering Patrick Chokron will present on the benefits of combining both tumor assessment approaches at the upcoming Immunomodulatory Therapeutic Antibodies for Cancer conference, August 13-15, 2013 in Boston.

Chokron’s presentation, “Image Assessment in Immunotherapeutic Trials: Combining irRC and RECIST 1.1,” will take place at the Hilton Boston Back Bay Hotel on Thursday, August 15, 2013 at 12:00 p.m.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos